Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

被引:0
|
作者
Papic, Ivan [1 ]
Bistrovic, Petra [2 ]
Keres, Tatjana [3 ]
Hadziabdic, Maja Ortner [4 ]
Lucijanic, Marko [5 ,6 ,7 ]
机构
[1] Univ Hosp Dubrava, Pharm Dept, Zagreb, Croatia
[2] Univ Hosp Dubrava, Cardiol Dept, Zagreb, Croatia
[3] Univ Hosp Dubrava, Intens Care Dept, Zagreb, Croatia
[4] Univ Zagreb, Fac Pharm & Biochem, Ctr Appl Pharm, Zagreb, Croatia
[5] Univ Hosp Dubrava, Hematol Dept, Av Gojka Suska 6, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Internal Med Dept, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
Remdesivir; corticosteroids; prognosis; dexamethasone; methylprednisolone; prednisone;
D O I
10.1080/14656566.2024.2320255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionWe aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution.MethodsWe retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ConclusionPatterns of corticosteroid use differ regarding the use of remdesivir and may moderate its association with survival among severe and critical COVID-19 patients.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [21] Effectiveness of Remdesivir Treatment Protocols Among Patients Hospitalized with COVID-19: A Target Trial Emulation
    Breskin, Alexander
    Wiener, Catherine
    Adimora, Adaora A.
    Brown Jr, Robert S.
    Landis, Charles
    Reddy, K. Rajender
    Verna, Elizabeth C.
    Crawford, Julie M.
    Mospan, Andrea
    Fried, Michael W.
    Brookhart, M. Alan
    EPIDEMIOLOGY, 2023, 34 (03) : 365 - 375
  • [22] Use of remdesivir for COVID-19 in patients with hematologic cancer
    Alexandra Martin-Onraët
    Corazón Barrientos-Flores
    Diana Vilar-Compte
    Carolina Pérez-Jimenez
    Pamela Alatorre-Fernandez
    Clinical and Experimental Medicine, 2023, 23 : 2231 - 2238
  • [23] Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience
    Russo, Alessandro
    Binetti, Erica
    Borrazzo, Cristian
    Cacciola, Elio Gentilini
    Battistini, Luigi
    Ceccarelli, Giancarlo
    Mastroianni, Claudio Maria
    D'Ettorre, Gabriella
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (17)
  • [24] Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19
    Caffrey, Aisling R.
    Liao, J. Xin
    Lopes, Vrishali V.
    LaPlante, Kerry L.
    Appaneal, Haley J.
    COVID, 2023, 3 (02): : 198 - 217
  • [25] Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19
    Falcone, Marco
    Suardi, Lorenzo Roberto
    Tiseo, Giusy
    Barbieri, Chiara
    Giusti, Lisa
    Galfo, Valentina
    Forniti, Arianna
    Caroselli, Claudio
    Della Sala, Leonardo
    Tempini, Sara
    Okoye, Chukwuma
    Monzani, Fabio
    Menichetti, Francesco
    CLINICAL THERAPEUTICS, 2022, 44 (03) : 364 - 373
  • [26] Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir
    Stoeckle, Kate
    Witting, Britta
    Kapadia, Shashi
    An, Anjile
    Marks, Kristen
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (01) : 384 - 387
  • [27] Clinical Outcomes Associated With Methylprednisolone in Mechanically Ventilated Patients With COVID-19
    Nelson, Brian C.
    Laracy, Justin
    Shoucri, Sherif
    Dietz, Donald
    Zucker, Jason
    Patel, Nina
    Sobieszczyk, Magdalena E.
    Kubin, Christine J.
    Gomez-Simmonds, Angela
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (09) : E367 - E372
  • [28] Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
    Wong, Carlos K. H.
    Lau, Kristy T. K.
    Au, Ivan C. H.
    Xiong, Xi
    Chung, Matthew S. H.
    Leung, Belle Y. C.
    Lau, Eric H. Y.
    Cowling, Benjamin J.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [29] Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19
    Jackson, Ian
    Jaradeh, Hadi
    Aurit, Sarah
    Aldamen, Ali
    Narechania, Shraddha
    Destache, Christopher
    Velagapudi, Manasa
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 119 : 47 - 52
  • [30] Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients
    Leegwater, E.
    Moes, D. J. A. R.
    Bosma, L. B. E.
    Ottens, T. H.
    van der Meer, I. M.
    van Nieuwkoop, C.
    Wilms, E. B.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (06)